Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has disclosed Current Deferred Revenue for 4 consecutive years, with $33.0 million as the latest value for Q1 2026.

  • For Q1 2026, Current Deferred Revenue rose 91.2% year-over-year to $33.0 million; the TTM value through Mar 2026 reached $33.0 million, up 91.2%, while the annual FY2025 figure was $27.2 million, 37.78% up from the prior year.
  • Current Deferred Revenue hit $33.0 million in Q1 2026 for Phathom Pharmaceuticals, up from $27.2 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $33.0 million in Q1 2026 and bottomed at $276000.0 in Q2 2023.
  • Average Current Deferred Revenue over 4 years is $16.6 million, with a median of $18.5 million recorded in 2024.
  • Year-over-year, Current Deferred Revenue soared 3490.58% in 2024 and then grew 4.79% in 2025.
  • Phathom Pharmaceuticals' Current Deferred Revenue stood at $7.1 million in 2023, then skyrocketed by 178.12% to $19.8 million in 2024, then surged by 37.78% to $27.2 million in 2025, then rose by 21.16% to $33.0 million in 2026.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $33.0 million, $27.2 million, and $24.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.